3 Key Takeaways
Plain English Summary- 01Core Finding
Gut- and gut-vascular barriers, systemic and hepatic lipopolysaccharide abundance and zonal transcriptional changes were assessed with multiplexed spatial single-cell analysis and transcriptomics.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
What This Means for You
Ours study found chronic hepatic metabolic stress induced by PD. Evidence of hepatic glucotoxicity and oxidative stress as instigators for systemic metabolic inflammation induced by PD suggests that similar pathologic mechanisms could also contribute to increased cardiometabolic risk on chronic PD.
The Discovery
Healthy mice and mice with chronic kidney disease (5/6 nephrectomy C57BL/6 aged 12-14 weeks) underwent seven weeks of PD. Combining morphologic studies, untargeted tissue proteomics, targeted plasma metabolomics and spatial transcriptomics, we assessed hepatic molecular and metabolic effects of PD. Gut- and gut-vascular barriers, systemic and hepatic lipopolysaccharide abundance and zonal transcriptional changes were assessed with multiplexed spatial single-cell analysis and transcriptomics. Intraperitoneally administered glucose during PD was rapidly taken up by the liver and induced hepatic metabolic inflammation. Portal-venous glucose overload bypassing the gastrointestinal tract resulted in increased glucose-to-cholesterol shunting with elevated plasma cholesterol levels, despite the absence of hepatic steatosis or glycogen storage. Increased oxidative stress and endotoxin load were associated with reduced hepatic Kupffer cell numbers without increased gut permeability.
How It Works, Simply
This nephrology research focuses on LDL cholesterol · Inflammation. Researchers evaluated it using an in vivo animal model (Preclinical discovery) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Gut- and gut-vascular barriers, systemic and hepatic lipopolysaccharide abundance and zonal transcriptional changes were assessed with multiplexed spatial single-cell analysis and transcriptomics.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models
In vivo animal model (Preclinical discovery) · Preclinical
Biological Pathway & Modality
LDL cholesterol · Inflammation
Intervention: Peritoneal dialysis induces hepatic metabolic stress as an instigator for systemic
Experimental Findings & Endpoints
Healthy mice and mice with chronic kidney disease (5/6 nephrectomy C57BL/6 aged 12-14 weeks) underwent seven weeks of PD.
Combining morphologic studies, untargeted tissue proteomics, targeted plasma metabolomics and spatial transcriptomics, we assessed hepatic molecular and metabolic effects of PD. Gut- and gut-vascular barriers, systemic and hepatic lipopolysaccharide abundance and zonal transcriptional changes were assessed with multiplexed spatial single-cell analysis and transcriptomics.
Intraperitoneally administered glucose during PD was rapidly taken up by the liver and induced hepatic metabolic inflammation. Portal-venous glucose overload bypassing the gastrointestinal tract resulted in increased glucose-to-cholesterol shunting with elevated plasma cholesterol levels, despite the absence of hepatic steatosis or glycogen storage.
Increased oxidative stress and endotoxin load were associated with reduced hepatic Kupffer cell numbers without increased gut permeability.
Clinical Translation & Practice Context
Ours study found chronic hepatic metabolic stress induced by PD.
Evidence of hepatic glucotoxicity and oxidative stress as instigators for systemic metabolic inflammation induced by PD suggests that similar pathologic mechanisms could also contribute to increased cardiometabolic risk on chronic PD.
The Bottom Line · Clinical Pearl
“Ours study found chronic hepatic metabolic stress induced by PD.”
Published in Kidney International · Current Stage: Preclinical